Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJHM1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 3	MAR 16	CASREACT coverage extended
NEWS 4	MAR 20	MARPAT now updated daily
NEWS 5	MAR 22	LWPI reloaded
NEWS 6	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 7	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS 8	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS 9	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS 10	APR 30	CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS 11	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS 12	MAY 01	New CAS web site launched
NEWS 13	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 14	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 15	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 16	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 17	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 18	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS 19	JUN 27	CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS 20	JUN 29	STN Viewer now available
NEWS 21	JUN 29	STN Express, Version 8.2, now available
NEWS 22	JUL 02	LEMBASE coverage updated
NEWS 23	JUL 02	LMEDLINE coverage updated
NEWS 24	JUL 02	SCISEARCH enhanced with complete author names
NEWS 25	JUL 02	CHEMCATS accession numbers revised
NEWS 26	JUL 02	CA/CAplus enhanced with utility model patents from China

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 4 MAY 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:13:18 ON 02 JUL 2007

=> FILE REGISTRY
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:13:28 ON 02 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 JUL 2007 HIGHEST RN 940612-32-8
DICTIONARY FILE UPDATES: 1 JUL 2007 HIGHEST RN 940612-32-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10564844a.str



chain nodes :
10 11 24 25 26 27 28 29 30
ring nodes :
1 2 3 4 5 6 7 8 9 12 13 14 15 16 17 18 19 20 21 22 23
chain bonds :
1-10 3-11 7-18 11-12 14-25 22-24 25-30 25-26 26-27 27-28 28-29
ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 12-13 12-17 13-14 14-15 15-16
16-17 18-19 18-23 19-20 20-21 21-22 22-23
exact/norm bonds :
3-11 5-7 6-9 7-8 7-18 8-9 11-12 25-30 25-26
exact bonds :
1-10 14-25 22-24 26-27 27-28 28-29
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17 18-19
18-23 19-20 20-21 21-22 22-23

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:CLASS 25:CLASS 26:CLASS 27:CLASS
28:CLASS 29:CLASS 30:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 16:13:51 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 1 TO 80
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 16:13:54 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 7 TO ITERATE

100.0% PROCESSED 7 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L3 1 SEA SSS FUL L1

=> d scan

L3 1 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, 3-[[3-(3-fluorophenyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]-N-(2-hydroxyethyl)- (9CI)
MF C19 H16 F N7 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.10	172.31

FILE 'CAPLUS' ENTERED AT 16:14:08 ON 02 JUL 2007

FILE COVERS 1907 - 2 Jul 2007 VOL 147 ISS 2
FILE LAST UPDATED: 1 Jul 2007 (20070701/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 1 L3

=> d l4 ibib abs hitstr

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:122890 CAPLUS
DOCUMENT NUMBER: 142:219305
TITLE: Preparation of triazolopyrimidines as glycogen synthase kinase 3 inhibitors
INVENTOR(S): Freyne, Eddy Jean Edgard; Love, Christopher John; Cooymans, Ludwig Paul; Vandermaesen, Nele; Buijnsters, Peter Jacobus Johannes Antonius; Willems, Marc; Embrechts, Werner Constant Johan
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005012307	A1	20050210	WO 2004-EP51455		20040712
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004260738	A1	20050210	AU 2004-260738		20040712
CA 2531333	A1	20050210	CA 2004-2531333		20040712
EP 1658292	A1	20060524	EP 2004-766189		20040712
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
CN 1823068	A	20060823	CN 2004-80020148		20040712
BR 2004012596	A	20060919	BR 2004-12596		20040712
US 2006205721	A1	20060914	US 2006-564844		20060113
NO 2006000678	A	20060210	NO 2006-678		20060210
PRIORITY APPLN. INFO.:			WO 2003-EP350310	A	20030716
			WO 2004-EP51455	W	20040712

OTHER SOURCE(S): CASREACT 142:219305; MARPAT 142:219305
GI



I



II

AB The title compds. I [ring A = Ph, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl; R1 = H, aryl, formyl, etc.; X = a direct bond, (CH2)n or (CH2)mX1aX1b (n = 1-4; m = 1-2; X1a = O, C(O), NR5; X1b = a direct bond, alkyl); R2 = cycloalkyl, Ph, 4-7 membered monocyclic heterocycle containing at least one heteroatom. selected from O, S or N, benzoxazolyl, etc.; R3 = halo, OH, (un)substituted alkyl, alkenyl or alkynyl, etc.; R4 = H, halo, OH, (un)substituted alkyl, etc.; R5 = H, alkyl, alkenyl], useful for the prevention or the treatment of diseases mediated through GSK3, were prepared E.g., a 4-step synthesis of II which showed pIC50 of > 8 against GSK3β and against GSK3α, was given. The pharmaceutical composition comprising the compound I is disclosed.

IT 840535-34-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazolopyrimidines as glycogen synthase kinase 3 inhibitors)

RN 840535-34-4 CAPLUS

CN Benzamide, 3-[[3-(3-fluorophenyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file registry
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION

FULL ESTIMATED COST	5.74	178.05

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.78	-0.78

FILE 'REGISTRY' ENTERED AT 16:14:46 ON 02 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 JUL 2007 HIGHEST RN 940612-32-8
DICTIONARY FILE UPDATES: 1 JUL 2007 HIGHEST RN 940612-32-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10564844b.str





chain nodes :
10 11 19 21
ring nodes :
1 2 3 4 5 6 7 8 9 12 13 14 15 16 17
chain bonds :
1-10 3-11 7-19 11-12 11-21
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 12-13 12-17 13-14 14-15 15-16
16-17
exact/norm bonds :
3-11 5-7 6-9 7-8 7-19 8-9 11-12 11-21
exact bonds :
1-10
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17

G1:Cy,H,Ak,C

G2:H,C,Cb,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 19:CLASS 21:CLASS

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR



G1 Cy,H,Ak,C
G2 H,C,Cb,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l5
SAMPLE SEARCH INITIATED 16:15:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 132 TO ITERATE

100.0% PROCESSED 132 ITERATIONS 28 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**
PROJECTED ITERATIONS: 1951 TO 3329
PROJECTED ANSWERS: 243 TO 877

L6 28 SEA SSS SAM L5

=> d scan

L6 28 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, 3-[5-[[3-(5-oxazolyl)phenyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI)
MF C21 H16 N8 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 28 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzoic acid, 2-(acetylamino)-5-[[3-[3-[[(methoxyacetyl)amino]methyl]phenyl]-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]-, methyl ester (9CI)
MF C24 H24 N8 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l5 full sss

FULL SEARCH INITIATED 16:17:44 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2448 TO ITERATE

100.0% PROCESSED 2448 ITERATIONS 601 ANSWERS
SEARCH TIME: 00.00.01

L7 601 SEA SSS FUL L5

=> d scan

L7 601 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, 4-[[3-[3-[(butylamino)sulfonyl]phenyl]-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]-N-[2-(diethylamino)ethyl]- (9CI)
MF C27 H35 N9 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	173.90	351.95

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.78

FILE 'CAPLUS' ENTERED AT 16:17:58 ON 02 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 2 Jul 2007 VOL 147 ISS 2
FILE LAST UPDATED: 1 Jul 2007 (20070701/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s d7
L8 2492 D7

=> s l7
L9 8 L7

=> d l9

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:884440 CAPLUS
DN 145:293080
TI Preparation and GSK-3 modulation of 2,4,5-trisubstituted pyrimidine and bicyclic 2-aminopyrimidine derivatives
IN Sebo, Lubomir; Kahl, Jeffrey; Lum, Christopher; Pei, Yazhong; Pryor, Kent E.; Urban, Jan; Jones, Bryan; Sullivan, Robert
PA Kemia, Inc., USA
SO PCT Int. Appl., 119pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006091737	A1	20060831	WO 2006-US6447	20060223

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2005-656265P	P	20050224	
US 2005-691519P	P	20050617	
US 2005-725369P	P	20051011	

OS MARPAT 145:293080
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l9 1-8 ibib abs hitstr

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:884440 CAPLUS
DOCUMENT NUMBER: 145:293080
TITLE: Preparation and GSK-3 modulation of 2,4,5-trisubstituted pyrimidine and bicyclic 2-aminopyrimidine derivatives
INVENTOR(S): Sebo, Lubomir; Kahl, Jeffrey; Lum, Christopher; Pei, Yazhong; Pryor, Kent E.; Urban, Jan; Jones, Bryan; Sullivan, Robert
PATENT ASSIGNEE(S): Kemia, Inc., USA
SOURCE: PCT Int. Appl., 119pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006091737	A1	20060831	WO 2006-US6447	20060223

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:		
US 2005-656265P	P	20050224
US 2005-691519P	P	20050617
US 2005-725369P	P	20051011

OTHER SOURCE(S): MARPAT 145:293080
GI



I



II

AB 2,4,5-Trisubstituted pyrimidine and bicyclic 2-aminopyrimidine derivs. I, wherein A is (un)substituted alkyl, halo, cyano, nitro, amine; B and C are independently NH, CH2 or carbonyl; R1 is (un)substituted cycloalkyl or cycloalkenyl; R2 is (un)substituted Me, (un)substituted cycloalkyl, (un)substituted cycloalkenyl groups are prepared Thus, II was prepared and displayed >40% inhibition in either GSK-3α or GSK-3β assay at 10 μM. Due to their ability to modulate GSK-3 activity, I can be used as prodrugs in the treatment of CNS diseases, such as Alzheimer's disease and mood disorders, and metabolic diseases, such as insulin requiring states.

IT 908299-40-1P 908299-41-2P 908299-45-6P
908299-52-5P 908299-60-5P 908299-63-8P
908299-66-1P 908299-69-4P 908299-71-8P
908299-72-9P 908300-03-8P 908300-05-0P
908300-11-8P 908300-13-0P 908300-19-6P
908300-33-4P 908300-43-6P 908300-44-7P
908300-48-1P 908300-49-2P 908300-70-9P
908301-54-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)



RN 908300-44-7 CAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5-[(3-phenyl-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)amino]- (9CI) (CA INDEX NAME)



RN 908300-48-1 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 5-[[3-(2,3-dihydro-1H-inden-5-yl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]- (9CI) (CA INDEX NAME)



RN 908300-49-2 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-(2,3-dihydro-1H-inden-5-yl)-N-1H-indazol-6-yl- (9CI) (CA INDEX NAME)



RN 908300-70-9 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-1H-benzotriazol-5-yl-3-phenyl- (9CI) (CA INDEX NAME)



RN 908301-54-2 CAPLUS
CN 1(3H)-Isobenzofuranone, 6-[(3-phenyl-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:700145 CAPLUS
DOCUMENT NUMBER: 145:167276
TITLE: Preparation of triazolopyrimidine derivatives as serine-tyrosine and tyrosine kinases inhibitors
INVENTOR(S): Ludovici, Donald W.; Connors, Richard W.; Coats, Steven J.; Liu, Li; De Corte, Bart L.; Johnson, Dana L.; Schulz, Mark J.
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006076442	A2	20060720	WO 2006-US999	20060111
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2007015207	A1	20070118	US 2006-329642	20060111
PRIORITY APPLN. INFO.:			US 2005-644466P	P 20050114

OTHER SOURCE(S): MARPAT 145:167276
GI

CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 900797-65-1P 900797-71-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of triazolopyrimidine derivs. as serine-tyrosine and tyrosine kinases inhibitors)
RN 900797-65-1 CAPLUS
CN Benzoic acid, 3-[[3-(2,3-dihydro-1H-inden-5-yl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]- (9CI) (CA INDEX NAME)



RN 900797-71-9 CAPLUS
CN 1-Propanol, 3-[4-[[3-(2,3-dihydro-1H-inden-5-yl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]phenoxy]-, 4-methylbenzenesulfonate (ester) (9CI) (CA INDEX NAME)



L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:699866 CAPLUS
DOCUMENT NUMBER: 145:167273
TITLE: Preparation of triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
INVENTOR(S): Love, Christopher John; Cooymans, Ludwig Paul; Vandermaesen, Nele
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006075023	A2	20060720	WO 2006-EP50206	20060113
WO 2006075023	A3	20060928		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: EP 2005-100221 A 20050114

OTHER SOURCE(S): MARPAT 145:167273

GI



I



II

AB Title compds. represented by the formula I [wherein ring A = Ph, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl; R1 = H, aryl, formyl, alkyl, etc.; R2 = cycloalkyl, Ph, benzoxazolyl, etc.; X = a direct bond, -(CH2)m- or -(CH2)n-Xa-Xb-; m = 1-4; n = 1 or 2; Xa = O, CO or NR3; Xb = a direct bond or alkyl; R3 = H, alkyl or alkenyl; and N-oxides, pharmaceutically acceptable salts, quaternary amines and stereoisomers thereof] were prepared as glycogen synthase kinase 3 (GSK3) inhibitors. For example, II was provided in a multi-step synthesis starting from reaction of 2,4-dichloro-5-nitropyrimidine with N-ethyl-N-(1-methylethyl)-2-propanamine. I were tested for inhibition of GSK3β and GSK3α. Thus, I and their pharmaceutical compns. are useful as for the treatment of glycogen synthase kinase 3 mediated disorders or diseases, such as mental and behavioral disorders, dementia and etc.

IT 900185-29-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of triazolopyrimidine derivs. as glycogen synthase kinase 3 inhibitors)

RN 900185-29-7 CAPLUS

CN Carbamic acid, [[3-[5-(phenylamino)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 900185-42-4 CAPLUS
CN Benzeneacetamide, 3-[5-(phenylamino)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:411903 CAPLUS
DOCUMENT NUMBER: 144:450727
TITLE: Preparation of HIV inhibiting bicyclic pyrimidine derivatives
INVENTOR(S): Janssen, Paul Adriaan Jan; Guillemont, Jerome Emile Georges; Paugam, Mikaeel; Delest, Bruno Francois Marie; Heeres, Jan; Lewi, Paulus Joannes
PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd., Ire.; Arts, Frank Xavier Jozef Herwig
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2006045828	A1	20060504	WO 2005-EP55589		20051027
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
AU 2005298637	A1	20060504	AU 2005-298637		20051027
CA 2577588	A1	20060504	CA 2005-2577588		20051027
PRIORITY APPLN. INFO.:			EP 2004-105419	A	20041029
			WO 2005-EP55589	W	20051027

OTHER SOURCE(S): MARPAT 144:450727
GI



I



II

AB HIV replication inhibitors I [-a1=a2-a3=a4- = -CH=CH-CH=CH-, -N=CH-CH=CH-, -N=CH-N=CH-, -N=CH-CH=N-, -N=N-CH=CH-; -b1=b2-b3=b4- = -CH=CH-CH=CH-, -N=CH-CH=CH-, -N=CH-N=CH-, -N=CH-CH=N-, -N=N-CH=CH-; -A-B- = -CR5=N-, -N=N-, -CH2CH2-, -CS-NH-, -CO-NH-, -CH=CH-; R1 = H, aryl, formyl, alkylcarbonyl, etc.; R2 = independently OH, halo, (un)substituted alkyl, alkenyl, etc.; R2a = CN, (un)substituted amino, (un)substituted alkyl, etc.; R3 = CN, amino, alkyl, etc.; R4 = independently halo, OH, (un)substituted alkyl, alkenyl, etc.; R5 = H, alkyl, aryl, etc.; Q = H, alkyl, halo, etc.; n, m = 0-4; and N-oxides, pharmaceutically acceptable addition salts, quaternary amines or stereoisomeric forms thereof] were prepared E.g., a multi-step synthesis of II, starting from 4-cyanoaniline and 4-(2-cyanoethenyl)-2-methylphenylamine, was given. The antiviral activity of the compds. I was evaluated in the presence of the wild type HIV and HIV mutants bearing mutations at the reverse transcriptase gene (data given). The invention also relates to the use of compds. I for the prevention or the treatment of HIV infection.

IT 885453-40-7P 885453-41-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of HIV inhibiting bicyclic pyrimidine derivs.)

RN 885453-40-7 CAPLUS

CN Benzonitrile, 4-[[3-[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 885453-41-8 CAPLUS

CN Benzonitrile, 4-[[3-[2-chloro-4-[(1E)-2-cyanoethenyl]-6-fluorophenyl]-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:122890 CAPLUS
DOCUMENT NUMBER: 142:219305
TITLE: Preparation of triazolopyrimidines as glycogen synthase kinase 3 inhibitors
INVENTOR(S): Freyne, Eddy Jean Edgard; Love, Christopher John; Cooymans, Ludwig Paul; Vandermaesen, Nele; Buijnsters, Peter Jacobus Johannes Antonius; Willems, Marc; Embrechts, Werner Constant Johan
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012307	A1	20050210	WO 2004-EP51455	20040712
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004260738	A1	20050210	AU 2004-260738	20040712
CA 2531333	A1	20050210	CA 2004-2531333	20040712
EP 1658292	A1	20060524	EP 2004-766189	20040712
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1823068	A	20060823	CN 2004-80020148	20040712
BR 2004012596	A	20060919	BR 2004-12596	20040712
US 2006205721	A1	20060914	US 2006-564844	20060113
NO 2006000678	A	20060210	NO 2006-678	20060210
PRIORITY APPLN. INFO.:			WO 2003-EP350310 A	20030716
			WO 2004-EP51455 W	20040712

OTHER SOURCE(S): CASREACT 142:219305; MARPAT 142:219305
GI



I



II

AB The title compds. I [ring A = Ph, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl; R1 = H, aryl, formyl, etc.; X = a direct bond, (CH2)n or (CH2)mX1aX1b (n = 1-4; m = 1-2; X1a = O, C(O), NR5; X1b = a direct bond, alkyl); R2 = cycloalkyl, Ph, 4-7 membered monocyclic heterocycle containing at least one heteroatom. selected from O, S or N, benzoxazolyl, etc.; R3 = halo, OH, (un)substituted alkyl, alkenyl or alkynyl, etc.; R4 = H, halo, OH, (un)substituted alkyl, etc.; R5 = H, alkyl, alkenyl], useful for the prevention or the treatment of diseases mediated through GSK3, were prepared E.g., a 4-step synthesis of II which showed pIC50 of > 8 against GSK3β and against GSK3α, was given. The pharmaceutical composition comprising the compound I is disclosed.

IT 840534-53-4P 840534-56-7P 840534-88-5P
840537-07-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of triazolopyrimidines as glycogen synthase kinase 3 inhibitors)

RN 840534-53-4 CAPLUS

CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-(3-bromophenyl)-3-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 840534-56-7 CAPLUS

CN 2-Propenoic acid, 3-[3-[[3-(3-fluorophenyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 840537-40-8 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-(4-chlorophenyl)-3-[3-(methoxymethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 840537-79-3 CAPLUS
CN Benzeneethanol, 3-[5-[[4-(2-aminoethyl)phenyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



RN 840537-80-6 CAPLUS
CN Benzeneethanol, 3-[5-[[4-[[(2,2,2-trifluoroethyl)amino]methyl]phenyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



RN 840537-85-1 CAPLUS
CN Benzeneacetonitrile, 3-[5-[[4-(aminomethyl)phenyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



RN 840537-88-4 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-(3-fluorophenyl)-N-[4-[[(2,2,2-trifluoroethyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:122889 CAPLUS
DOCUMENT NUMBER: 142:219304
TITLE: Preparation of triazolopyrimidines as glycogen synthase kinase 3 inhibitors
INVENTOR(S): Freyne, Eddy Jean Edgard; Love, Christopher John; Cooymans, Ludwig Paul; Vandermaesen, Nele; Buijnsters, Peter Jacobus Johannes Antonius; Willems, Marc; Embrechts, Werner Constant Johan
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012304	A2	20050210	WO 2004-EP51457	20040712
WO 2005012304	A3	20070426		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA				
AU 2004260739	A1	20050210	AU 2004-260739	20040712
CA 2531232	A1	20050210	CA 2004-2531232	20040712
CN 1938308	A	20070328	CN 2004-80020418	20040712
EP 1781659	A2	20070509	EP 2004-766191	20040712
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, LT, LV, MK				
US 2006183747	A1	20060817	US 2006-565065	20060117
PRIORITY APPLN. INFO.:			WO 2003-EP50314 A	20030716
			WO 2003-EP350314 A	20030716
			WO 2004-EP51457 W	20040712

OTHER SOURCE(S): CASREACT 142:219304; MARPAT 142:219304
GI

CN 2-Propen-1-one, 3-(dimethylamino)-1-[3-[[3-(3-fluorophenyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 842129-10-6 CAPLUS
CN 2-Propen-1-one, 3-(dimethylamino)-1-[3-[ethyl[3-(3-fluorophenyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]phenyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1984:472753 CAPLUS
DOCUMENT NUMBER: 101:72753
TITLE: 3,5-Disubstituted triazolopyrimidine derivatives
PATENT ASSIGNEE(S): S. S. Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 59062594	A	19840410	JP 1982-171172	19820930
JP 03003675	B	19910121		

PRIORITY APPLN. INFO.: JP 1982-171172 19820930
GI



AB Title derivs. I (R = Cl, MeO, PhO, MeNH, PhCH2S, HO, EtO, PhCH2NH, Me2N, pyrrolidino) were prepared by reduction of II, diazotization-cyclization, and optional reaction with R1H (R1 = R except Cl). Anticarcinogen test data on I were shown against Sarcoma 180 ascite tumor cells in mice. Thus,

hydrogenation of 1 g II in EtOH containing 1 g Raney Ni with 300-350 mL H, filtration, concentration, dissoln. in 2N HCl-H2O-AcOH, addition of 0.16 g NaNO2 in
H2O during 15 min under ice cooling, and stirring 30 min under ice cooling 1 h at room temperature gave 0.48 g I (R = Cl) (III). Stirring 0.3 g III with 30 mL MeOH and 0.3 g K2CO3 4 h at room temperature gave 58% I (R = MeO).

IT 91322-11-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 91322-11-1 CAPLUS

CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N,3-diphenyl- (9CI) (CA INDEX NAME)



L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1956:20104 CAPLUS
DOCUMENT NUMBER: 50:20104
ORIGINAL REFERENCE NO.: 50:4159i,4160a-f
TITLE: Purines. V. The preparation of certain 2,9-substituted purines and azapurines
AUTHOR(S): Dille, K. L.; Sutherland, M. L.; Christensen, B. E.
CORPORATE SOURCE: Oregon State Coll., Corvallis
SOURCE: Journal of Organic Chemistry (1955), 20, 171-7
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB cf. C.A. 49, 12130h, 13256a. Adding 10 g. PhNH2 in 200 cc. absolute EtOH to 5 g. 2,4-di-chloro-5-nitropyrimidine (I) in 20 cc. absolute EtOH with stirring and refluxing the mixture 45 min. give 94% 2,4-di-anilino-5-nitropyrimidine (II), fluffy light yellow needles, m. 203-4°. Reducing 2 g. II in 150 cc. absolute EtOH 3-6 h. with 2 g. Raney Ni gives 70% 2,4-dianilino-5-aminopyrimidine (III), m. 165-8° (decomposition). Adding 0.16 g. NaNO2 to 0.57 g. III dissolved in 400 cc. 5% AcOH at 10-20°, stirring the mixture 15 min., and adjusting the solution to pH 8-9 give 62% 3-phenyl-5-anilino-1H-v-triazolo[d]pyrimidine, light green needles, m. 195°. Refluxing 0.91 g. III in 10 cc. 90% HCO2H 15 min., evaporating the HCO2H, dissolving the residue in 5 cc. H2O, and adjusting the solution to pH 7-8 with NH4OH give 0.97 g. 2,4-dianilino-5-formamidopyrimidine (IV), needles, m. 193.5-5° (the rate of heating affects the m.p.; another determination gives 187-9°, resolidifying and remelting at 215°). Gently refluxing 1 g. IV 15 min. with 10 cc. HCO-NH2, adding 10 cc. H2O, and adjusting the solution to pH 7-8 give 92% 2-anilino-9-phenylpurine, needles, m. 215-16°. Adding slowly 5 g. I in 20 cc. EtOH to 8.5 cc. PrNH2 in 100 cc. EtOH and refluxing the mixture 0.5 h. give 91% 2,4-di-propylamino-5-nitropyrimidine (V), m. 121-2°, which (2 g.) is reduced in 115 cc. MeOH with 2 g. Raney Ni 2-3 h. at 30 lb. and the residue of the filtered and evaporated solution treated with H2SO4, giving 72% 2,4-dipropylamino-5-aminopyrimidine sulfate (VI). Stirring 1.84 g. VI in 200 cc. H2O containing 2 drops H2SO4 0.5 h. at 10-20° with 0.55 g. NaNO2 and adjusting the solution to pH 7-8 give 49% 3-propyl-5-propylamino-1H-v-triazolo[d]pyrimidine, long needles, m. 97.5-8°. Refluxing the reduction product of 2.65 g. V with 15 cc. HCO2H, adding 5 cc. H2O, and adjusting the solution to pH 7-8 give 1.5 g. 2,4-dipropylamino-5-formamidopyrimidine, shiny platelets, m. 159.5-60.5°, which (0.94

g.), refluxed 15 min. with 10 cc. HCONH2, gives 0.35 g. 2-propylamino-9-propyl-purine, m. 84-5°. Refluxing 8.25 g. 2-chloro-4-(2-hydroxyethylamino)-5-nitropyrimidine in 120 cc. EtOH saturated with NH3 in an NH3 atmospheric gives 93% 2-amino-4-(2-hydroxyethylamino)-5-nitropyrimidine (VII), m. 192-4°. Reduction of 2 g. VII in MeOH 1-2 h. with Raney Ni at 30 lb. and acidification of the filtered and concentrated solution with H2SO4 give 1.46 g. sulfate, m. 169-70°, which, treated with NaNO2, gives 65% 3-(2-hydroxyethyl)-5-amino-1H-v-triazolo[d]pyrimidine, m. 220-1°. Reducing 4 g. VII with 5 g. Raney Ni in 200 cc. MeOH and concentrating the filtered solution give 1 g. 2,5-diamino-4-(2-hydroxyethylamino)pyrimidine, m. 140-1.5°, which, refluxed 15 min. with 10 cc. HCO2H, gives 0.3 g. 5-formamido derivative (VIII), m. 165-6°. Refluxing 0.55 g. VIII 15 min. with 10 cc. HCONH2 gives 0.3 g. 2-amino-9-(2-formyloxyethyl)purine, needles, m. 172-3°. Adding AcOH dropwise to 2 g. 2-mercapto-4,5-diaminopyrimidine in 1.2 l. H2O containing 2 g. NaNO2 at 30° gives 1.6 g. 5-mercapto-1H-v-triazolo[d]pyrimidine, exploding on a m.p. block.

IT 91322-11-1P, 3H-v-Triazolo[4,5-d]pyrimidine, 5-anilino-3-phenyl-
RL: PREP (Preparation)
(preparation of)

RN 91322-11-1 CAPLUS

CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N,3-diphenyl- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 16:13:18 ON 02 JUL 2007)

FILE 'REGISTRY' ENTERED AT 16:13:28 ON 02 JUL 2007
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 1 S L1 FULL

FILE 'CAPLUS' ENTERED AT 16:14:08 ON 02 JUL 2007
L4 1 S L3

FILE 'REGISTRY' ENTERED AT 16:14:46 ON 02 JUL 2007
L5 STRUCTURE UPLOADED
L6 28 S L5
L7 601 S L5 FULL SSS

FILE 'CAPLUS' ENTERED AT 16:17:58 ON 02 JUL 2007
L8 2492 S D7
L9 8 S L7

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	57.57	409.52

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL

	ENTRY	SESSION
CA SUBSCRIBER PRICE	-6.24	-7.02

STN INTERNATIONAL LOGOFF AT 16:33:35 ON 02 JUL 2007